ArticleCurrent neurology and neuroscience reports2014
Ocular myasthenia gravis: controversies and updates.
Article in Current neurology and neuroscience reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Pooled it
- Association Between Immunotherapy and Generalization in Ocular Myasthenia Gravis as a Function of Antibody Status.Revista de neurologia · 2026Article
- Thymectomy in Ocular Myasthenia Gravis: Results Before and After Generalization and Prognostic Predictors of Outcomes.Journal of clinical medicine · 2025Article
- The assessment of the perceived stress and the quality of life in the patients with myasthenia gravis: The mediating role of the psychological capital and social support.Current journal of neurology · 2024Article
- Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis.Frontiers in molecular biosciences · 2024Review
- Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report.Experimental and therapeutic medicine · 2023Article
- Immunotherapy for ocular myasthenia gravis: an observational study in Japan.Therapeutic advances in neurological disorders · 2023Article
- Clinical characteristics of ocular myasthenia gravis and outcomes of secondary generalisation: a systematic review protocol.BMJ open · 2022Article
- Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis.Orphanet journal of rare diseases · 2022Article
- Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes.BMC neurology · 2022Article
- Effects of Natural Products on Neuromuscular Junction.Current neuropharmacology · 2022Review
- Ocular myasthenia gravis saccades as a measure of extraocular muscle function.Frontiers in ophthalmology · 2022Article
- Advocating Patient-Centred Research in Ocular Myasthenia Gravis (OMG): A Call for an OMG Research Consortium.Frontiers in ophthalmology · 2022Article
- Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Observational
- Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?Journal of neurology · 2021Article
- Patients With Myasthenia Gravis With Acute Onset of Dyspnea: Predictors of Progression to Myasthenic Crisis and Prognosis.Frontiers in neurology · 2021Article
- Prognostic predictors of remission in ocular myasthenia after thymectomy.Journal of thoracic disease · 2020Article
- Controversies in Ocular Myasthenia Gravis.Frontiers in neurology · 2020Review
- miR-30e-5p as predictor of generalization in ocular myasthenia gravis.Annals of clinical and translational neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of patients with myasthenia gravis (MG) initially present with ocular symptoms. An unresolved question is whether there are clinical features at onset to guide clinicians to predict an individual patient's conversion risk from ocular MG (OMG) to generalized disease, or "secondary generalized MG" (SGMG), that is, a prognostic model. In light of the emerging theory that early corticosteroids may have a risk-modifying effect, the factors associated with secondary SGMG previously reported should be revisited. Studies showing potential risk-modifying effects of corticosteroids are useful, though flawed, owing to the heterogeneous retrospective studies and methods of reporting. Updates on other potential immunosuppressive agents are also discussed. Thymectomy in OMG has been recently reported in a few studies to be useful. MG associated with antibodies to muscle-specific kinase, usually associated with severe generalized MG, can cause a pure OMG syndrome. Recent serological developments in seronegative patients have also revealed antibodies to clustered anti-acetylcholine receptor and lipoprotein receptor-related protein-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.